PYRAZOLO[1,5-A]PYRIMIDINYLCARBOXAMIDES AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS Russian patent published in 2023 - IPC C07D487/04 A61K31/519 A61P25/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, in which R¹ in each case independently means C_1-4 alkyl; R² means hydrogen; R⁴ at each occurrence independently means hydrogen, C_1-4 alkyl or cyclopropyl; R⁷ independently in each occurrence means halogen, cyanogroup, C_1-4 alkyl, C_1-4 haloalkyl, C_1-4 alkoxy, -O-(C_3-6 cycloalkyl), -O-(C_1-6 alkylene)-C_1-6 alkoxy, -C(O)N(R⁴)₂ or 5–10 membered heteroaryl having one to three heteroatoms selected from nitrogen and oxygen; X¹ means -C(O)N(H)(C_1-6 haloalkylene)-ψ , where ψmeans connection with A¹; where A¹ means 3–5-membered saturated carbocyclyl, C_1-8 alkyl or C_2-6 alkynyl; A² means one of the following: phenyl, 1, 2 or 3 times substituted with R⁷; or a cyclic group selected from the group consisting of 5–6 membered heterocyclyl having one to two heteroatoms selected from nitrogen, oxygen and sulfur, selected from piperidinyl, pyrrolidinyl, morpholinyl, benzoimidazolyl, pyridinyl, thiazolyl, benzoxazolyl, oxazolyl, isoxazolyl, thiophenyl, furanyl, pyrazolyl, benzodioxolyl, isothiazolyl; 5–6 membered oxoheterocyclyl selected from oxazolidinyl, imidazolidinyl, tetrahydropyrimidinyl; each of which is optionally 1, 2 or 3 times substituted with R⁷; and n is either 1 or 2. The invention also relates to the compound of formula IV and specific compounds presented in the claims. The invention relates to a pharmaceutical composition capable of activating glucocerebrosidase comprising an effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

EFFECT: pyrazolo[1,5-a]pyrimidinylcarboxamide compounds capable of activating glucocerebrosidase and used to treat Gaucher's disease, Parkinson's disease and Lewy body disease.

40 cl, 5 tbl